B. Metzler seel. Sohn & Co. AG Sells 4,388 Shares of IDEXX Laboratories, Inc. $IDXX

B. Metzler seel. Sohn & Co. AG lowered its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 20.6% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,947 shares of the company’s stock after selling 4,388 shares during the quarter. B. Metzler seel. Sohn & Co. AG’s holdings in IDEXX Laboratories were worth $10,827,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the company. WealthCollab LLC bought a new position in shares of IDEXX Laboratories in the second quarter valued at approximately $30,000. J.Safra Asset Management Corp acquired a new position in shares of IDEXX Laboratories in the 3rd quarter worth approximately $31,000. Armstrong Advisory Group Inc. grew its position in IDEXX Laboratories by 55.9% during the 3rd quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock worth $34,000 after acquiring an additional 19 shares during the last quarter. Salomon & Ludwin LLC bought a new stake in IDEXX Laboratories during the 3rd quarter worth approximately $35,000. Finally, Greykasell Wealth Strategies Inc. acquired a new stake in IDEXX Laboratories during the 3rd quarter valued at $35,000. 87.84% of the stock is owned by institutional investors.

Insider Activity

In other IDEXX Laboratories news, EVP George Fennell sold 11,345 shares of the business’s stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the completion of the sale, the executive vice president directly owned 9,823 shares of the company’s stock, valued at approximately $6,352,730.56. The trade was a 53.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Nimrata Hunt sold 1,758 shares of the company’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $634.57, for a total transaction of $1,115,574.06. Following the transaction, the executive vice president owned 18,141 shares in the company, valued at approximately $11,511,734.37. The trade was a 8.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 45,957 shares of company stock worth $29,862,109. Corporate insiders own 0.98% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on IDXX. Wall Street Zen downgraded IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. UBS Group lowered their target price on IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a research note on Tuesday, February 3rd. Piper Sandler cut their price target on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a report on Monday, February 9th. Barclays reduced their price target on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Finally, BTIG Research decreased their price objective on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a report on Tuesday, February 3rd. Seven research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $783.33.

IDEXX Laboratories Stock Down 1.7%

Shares of IDXX opened at $608.41 on Friday. The business’s fifty day moving average price is $666.94 and its two-hundred day moving average price is $668.42. The firm has a market capitalization of $48.44 billion, a price-to-earnings ratio of 46.55, a PEG ratio of 3.70 and a beta of 1.66. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $769.98. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Monday, February 2nd. The company reported $2.92 earnings per share for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The firm had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter in the previous year, the firm earned $2.53 EPS. The company’s revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.